Huahai Pharmaceutical secures NMPA approval for two new drugs

Zhejiang Huahai Pharmaceutical Co., Ltd. recently obtained drug registration certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection.

The Candesartan Cilexetil and Hydrochlorothiazide Tablets (II), approved as a Class 3 chemical drug, are indicated for hypertension. The company invested approximately RMB 11.28 million in the research and development of this product, which addresses a market estimated at RMB 149 million in China for 2024.

The Roxatidine Acetate Hydrochloride for Injection, also approved as a Class 3 chemical drug, is intended for upper gastrointestinal bleeding. Zhejiang Huahai Pharmaceutical invested approximately RMB 4.31 million in R&D for this product, part of a domestic market projected to reach RMB 1.18 billion in 2024.

These approvals are expected to enrich the company's product lines and enhance its market competitiveness. Both products are deemed to have passed consistency evaluations. The company cautions investors about potential risks stemming from policy changes and market uncertainties affecting production and sales.